This study examined changes in prostate disease screening (prostatic-specific antigen [PSA] testing), prostate biopsy testing, and prostate cancer diagnoses during the COVID-19 pandemic through December 2020.
The primary objective was to compare the overall diagnostic performance, presented as detection rate of 68Ga-PSMA-HBED-CC positron emission tomography/magnetic resonance imaging (PSMA PET/MRI) versus conventional, multiparametric MRI (mpMRI) in a population of patients with biochemically recurrent prostate cancer.
In randomized clinical trials, the androgen receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety, and patient-reported outcomes (PROs) of enzalutamide in mCRPC patients in a real-world European setting.
Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) in patients with non-metastatic muscle-invasive bladder cancer (MIBC) confers an absolute survival benefit of 5-10%. There is evidence that molecular differences between tumors may impact response to therapy, highlighting a need for clinically validated biomarkers to predict response to NAC.
The association between tobacco use and urothelial cancer of the bladder is well known. Given the worsening tobacco epidemic, here we make the case for systematic targeted points of intervention for urologists and other professionals to intervene against bladder cancer.
(UroToday.com) As one of the final sessions of the second day of the 2021 ANZUP Annual Scientific Meeting, the Crossfire Debate included a focus on the relative importance of waiting for overall survival data before acting upon the results of clinical trials.
(UroToday.com) As one of the final sessions of the second day of the 2021 ANZUP Annual Scientific Meeting, the Crossfire Debate included a focus on the relative importance of waiting for overall survival data before acting upon the results of clinical trials.
(UroToday.com) In a session entitled Clearer Vision chaired by Dr. Bertrand Tombal at the 2021 ANZUP Annual Scientific Meeting, Dr. Alison Birtle discussed what she described as wishful thinking in genitourinary oncology, with a focus on optimal therapy for systemic therapy in upper tract urothelial carcinoma (UTUC).
(UroToday.com) In a session entitled Clearer Vision chaired by Dr. Bertrand Tombal at the 2021 ANZUP Annual Scientific Meeting, Dr. Chris Parker presented on how multiparametric magnetic resonance imaging (MRI) became the mainstay of active surveillance for prostate cancer.
(UroToday.com) On the second day of the 2021 ANZUP Annual Scientific Meeting, one of the key sessions focused on what is happening for ANZUP trials. Ray Allen presented an update on the Consumer Advisory Panel (CAP) group. This group is composed of individuals with personal or indirect personal experiences with cancer who contribute expertise with a […]
